Patents by Inventor Ulla Grauschopf

Ulla Grauschopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200297919
    Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 24, 2020
    Inventors: Markus HEMMINGER, Ulla GRAUSCHOPF, Frank BAMBERG, Mayumi BOWEN, Robert MÜLLER, Flora FELSOVALYI, Denny CHRISTENSEN
  • Publication number: 20200282130
    Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 10, 2020
    Inventors: Markus HEMMINGER, Ulla GRAUSCHOPF, Frank BAMBERG, Mayumi BOWEN, Robert MÜLLER, Flora FELSOVALYI, Denny CHRISTENSEN
  • Publication number: 20180228895
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 9968676
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 15, 2018
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20170360891
    Abstract: The present invention provides a stable, isotonic, aqueous solution formulation comprising: (i) 0.1-0.5 mg/mL alpha-type interferon, preferably pegylated alpha-type interferon; (ii) 20 mM Acetate buffer system to maintain a pH of 6.0±0.5; (iii) 5-20 mM L-methionine; (iv) 120-150 mM sodium chloride; (v) 0.01-0.07 percent by weight of a surfactant effective to stabilize the alpha-type interferon, preferably pegylated alpha-type interferon against loss of its activity and (vi) an amount of water for injection sufficient to prepare a solution of the above-listed ingredients.
    Type: Application
    Filed: March 23, 2017
    Publication date: December 21, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulla Grauschopf, Michael Adler, Hanns-Christian Mahler, Felix Heise, Susanne Baroth
  • Publication number: 20160166689
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 9345661
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20140093512
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20130251725
    Abstract: The present invention relates to a stable liquid pharmaceutical formulation comprising 40 mg/ml to 200 mg/ml of an antibody against P-selectin; 0.01% to 0.1% of a poloxamer; 5 mM to 100 mM of a buffer; and 100 mM to 500 mM of at least one stabilizer; at a pH in the range from 4.5 to 7.0.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 26, 2013
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulla Grauschopf, Michael Adler, Hanns-Christian Mahler
  • Publication number: 20120321638
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: July 30, 2012
    Publication date: December 20, 2012
    Inventors: Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20110158987
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against Epidermal Growth Factor Receptor (EGFR), a process for the preparation and uses of the formulation.
    Type: Application
    Filed: December 23, 2010
    Publication date: June 30, 2011
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler
  • Publication number: 20110044977
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: July 27, 2010
    Publication date: February 24, 2011
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20100074903
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: September 15, 2009
    Publication date: March 25, 2010
    Inventors: Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch